TREATMENT OF METASTATIC LIVER TUMORS BY INTERMITTENT REPETITIVE INJECTION OF A ANGIOGENESIS INHIBITOR USING AN IMPLANTABLE PORT SYSTEM

TNP-470有望成为一种新型的抗肿瘤药物，它通过抑制肿瘤血管生成来防止肿瘤新生血管的形成。本实验采用VX_2肝癌转移瘤模型，观察TNP-470门静脉内注射对肿瘤的治疗作用。A组为对照组，B组为TNP-470重复皮下注射组，C、D、E组为TNP-470、阿霉素、TNP-470+阿霉素分别于接种后2天或3天注射5次。2周后，病理检查TNP-470的抑瘤效果，肿瘤生长数五组间无显著性差异。各组平均肿瘤大小依次为E、D、C、B、A，除E组与D组间差异有统计学意义（P<0.05）外，其余各组间差异均有统计学意义（P<0.05）。B、C、E组肿瘤内新生血管明显少于A、D组，提示TNP-470经储库系统间断重复注射治疗肝转移较全身给药更有效。

TNP-470 is expected as a new type of anticancer drug which prevents tumor neovascularization by acting as angiogenesis inhibitor. We attempted to evaluate anticancer effect of intermittent repetitive intraportal injection of TNP-470 for metastatic hepatic tumor models using VX2-carcinoma and considered usefulness and role of TNP-470.We used 25 Japanese white rabbits with metastatic hepatic tumors made by intraportal injection of tumor cells, and divided into five groups ; group A was control group, group B was treated by repetitive subcutaneous injection of TNP-470 and group C,D,E was treated by repetitive intraportal injection of TNP-470, adriamycin, TNP-470+adriamycin respectively 5 times at 2 or 3 days interval after tumor inoculation using portal reservoir systems. After 2 weeks, we examined anticancer effect of TNP-470 pathologically.In the number of grown tumors, there was no remarkable difference among five groups statisitically. But mean tumor size of each group is smaller in order of group E,D,C,B,A and the differences were significant (P<0.05) except between E and D group. And intratumoral neovascularization tended to be less in group B,C,E than in group A,D pathologically.We consider that intermittent repetitive injection of TNP-470 via reservoir system is more useful than systemic administration for liver metastasis.